Concerns have arisen over JAK inhibitors' cardiovascular safety relative to TNF inhibitors and other biologic agents for rheumatoid arthritis. Registry data from more than 50,000 European patients ...

The IMPACT trial reinforces the need to check for antiphospholipid syndrome in women after they experience stillbirth and is ...

Operating profit / (loss): Operating profit was $10.6 million for the three months ended 31 March 2025, compared to ($48.4) ...

The partners also announced filing acceptance of U.S. Biologics License Applications ... all rights to a biosimilar candidate referencing Cimzia® (certolizumab pegol). Xbrane’s shareholders ...

Interim Report January-March 2025, is as of today, available on the Company's website, FINANCIAL OVERVIEW FIRST QUARTER 2025* • Revenue amounted ...

Three other biologics for RA that have alternative mechanisms ... In addition, UCB has recently gained approval for certolizumab pegol (Cimzia) for the treatment of RA with a dosing regimen ...

Cimzia accounted for €1.7 billion of the ... has shown superiority to Cosentyx in a head-to-head trial, other new biologics with blockbuster sales forecasts are also aiming to steal psoriasis ...